RNA gene expression results from our novel immune competent breast cancer model provides several molecular indicators such as TNC and CXCL12 to direct a future combined “TIL‐matrix‐release‐and‐reactivate” strategy for improving ICT in breast cancer. Here, CXCL12 is linked to breast cancer.